Cero Therapeutics Holdings Inc (CERO)

$CERO https://www.srxglobalinc.com/news-events/press-releases/detail/147/srx-global-acquires-senior-secured-debt-in-cero-therapeutics-holdings-inc-an-innovative-cellular-immunotherapy-company-with-cancer-fighting-molecule-for-the-treatment-of-hematologic-cancers

$CERO How so? They simply take ownership of the drug IP. If that happens, shareholders are left holding an empty corporate shell with virtually no asset value. If the allow, Cero could push 4 times with a 30-day extention and then we would be into 2027. for anyone down 90% and more this is a dead cat, they need a private takeover offer.

$SRXH I can't believe since June 30 they added these $JMKE $VTGN $CERO Two penny stocks and a sandwich company that offers nothing different than a Subway. Pathetic!

$CERO , If cero unable to paid loan on october 2026 , that will allow a hostile take over by SRXH ? pipeline of cero at phase 1 and even good outcome to push $0.30 ish .., ! any bullish case for $30

$SRXH facts. Considering it’s trading at half of its “NAV” nothing can save this. People will have fun once the $11M is given to $CERO and they default , Srxh will become CERO 2.0 and fail

$CERO one more cent down to zero bid SELL

$SRXH The fun begins at $2-$3 when they start chasing! Remember we trade & make $ both ways not just hold like $MSTR We manage risks & crypto ain't our only investment uuuuuuuuu we have a lot of stuff going! $CERO $OPEN 💰 $3.40 NAV | 💵 $55M Cash 🔥 $20M Buyback / Up to 50% OS 🚫 ZERO Debt | 📉 Only ~19.5M Shares 💸 $0.05 Dividend | 📈 Revenue +27% 🤖 EMJX + Gen2 AI Treasury 🐾 Halo Improving | 💪 No Expected Raise 🚀 $6+ GAP FILL

$CERO Consensus Price Target $30.00 243,802.44% Upside According to the 3 analysts' twelve-month price targets for CERo Therapeutics, the average price target is $30.00. The highest price target for CERO is $30.00, while the lowest price target for CERO is $30.00. The average price target represents a forecasted upside of 243,802.44% from the current price of $0.01. -Source (Market Beat) .... I would be happy with 50 cents

$SRXH $CERO $OPEN $MRNA

$CERO Things are heating up.

$CERO Nice volume today ... Thanks to the management team at $SRXH !!!!!

$CERO I went ahead and picked up another 14K shares. I understand that this and some of my other investments are long plays, but I'm patient and have conviction they will play out. $SRXH $QBTS

$SRXH This is going to be LONG, For those of you that like to dig and do DD I would like to make you aware of a "situation" you might want to investigate regarding $SRXH and $CERO. For some history/context, I have bought and sold SRXH several times at a profit but am not in it now although I do have a limit buy order placed. However, I am a OG bagholder of CERO and traded it many times until the 1/20 reverse split in 6/2025. Watched it drop from $8 or so to 2ish then in Oct. 2025 it was halted and suspended from NASDAQ. It opened on OTC markets at about $.07 and has been there since trading at about $.01. Now what should interest you folks. CERO had cash at time of delisting but that cut them off from the "Bank" (thus some creative financing with SRXH). The CEO is Chris Ehrlich. Mr Ehrlich is also the CEO of another company... In 2024 Mr Ehrlich was part of an IPO for a SPAC (special purpose acquisition company). For those of you that do not know, a SPAC has 2

$SRXH $CERO well at least they like the news I guess and 28,000 traded on Friday so quite the increase 😳

$SRXH can't buy $CERO cause Robinhood doesn't have it 🙄

$SRXH $CERO overview of the SRX Global financing and pipeline details for anyone catching up:Financing: SRX Global raised $2.86M in a Series C preferred stock placement, funded via the assignment of CERO convertible notes to help inject liquidity and keep programs funded.The Platform: They're working on engineered "phagocytic CAR-T" therapies that use innate immune mechanisms (targeting Tim-4L) to clear tumors.Clinical Programs:• CERTAIN-T Trial (Lead asset: CER-1236) for AML, MDS, and MF. Already cleared first two dose cohorts with zero DLTs or CRS. Currently enrolling the third cohort. Early data showed cell expansion, a prolonged platelet transfusion-free interval in an MDS/AML patient, and tumor blast reduction down to 7% in an AML patient which successfully bridged them to a stem cell transplant.• Solid Tumors: FDA already cleared the IND for CER-1236 in ovarian cancer / solid tumors, setting up a second clinical program.

$CERO the only reason for $SRXH to take all this credit on CERO would be to dump their data and merge something into the shell. But their own stock performance is so bad maybe worst in the market who wants to give them another bullet and gun ?

$SRXH OK I promise this is my last post but I would certainly like to see a PR on why they purchased CERO notes from Keystone and let’s see that waiver of buyback restriction ASAP!!! One more point on the Series C/buyback issue. If the $2.8125M exact match means Keystone is indeed the Series C investor, there’s an important piece of context: Keystone already has an established financing relationship with SRX. These aren’t two parties that just met through the CERO transaction. That makes a buyback waiver/consent considerably more plausible, IMO. The Series C documents restrict SRX from repurchasing common stock, but they also specifically provide a mechanism for the Required Holders to consent to a repurchase. Keystone also knew SRX had already publicly authorized a $20M share-repurchase program when this Series C deal was negotiated. It would seem pretty strange for SRX to accidentally negotiate a new security that killed its own buyback without that issue being discussed. Could there already be a waiver/consent or side agreement? Possibly. But we haven’t found one, so it shouldn’t be stated as fact. Still, if Keystone is the Series C holder, their existing relationship with SRX makes obtaining that consent look a hell of a lot more realistic than it did when we thought these were completely unrelated investors. Now management just needs to clarify it. 🔎 $CERO

$SRXH Another interesting piece of the CERO puzzle. Keystone isn’t some random CERO lender that SRX suddenly encountered. Keystone already has a substantial financing relationship with SRX, including SRX’s equity-line arrangement. Now look at the timeline: Keystone finances SRX → Keystone finances CERO → SRX begins financing CERO → SRX now appears to acquire Keystone’s entire disclosed CERO note position. Keystone’s four disclosed CERO notes totaled exactly $2,812,500 — the exact principal amount of CERO notes SRX acquired Friday. The SRX filing redacts the Series C buyer, so we can’t definitively say it’s Keystone, but that exact match combined with their existing relationship is pretty damn compelling. I found no evidence Eric Jackson and Keystone/Fredric Zaino have a personal relationship — no golf buddies or mutual Drake obsession 😂 — but commercially, SRX and Keystone absolutely knew each other well before this transaction. This makes Friday’s deal look even less random. SRX appears to be deliberately consolidating CERO debt from a financing partner it already knows. Still leaves the million-dollar question: Why does SRX want this much CERO debt right now? Hopefully management explains the strategy soon, because there’s clearly more to unpack here than “SRX threw more money at CERO.” 🔎 $CERO

$SRXH If you want to understand how $SRXH manufactures value under its new holding company structure, look closely at yesterday’s closing of the CERo Therapeutics deal. This is one of many, Quietly growing extremely fast behind the scenes. Investing in different ways that makes them unique. But also not everything business is reflected by stock price with being an acquisition. 1, This wasn't a standard, boring acquisition. SRXH didn't just go out and buy retail shares of $CERO. They used institutional-grade structured finance to secure a massive advantage. 2, SRXH injected $750K in cash for a convertible note worth $937.5K, They engineered the note to convert into cheap equity under flexible pricing On Aug 28, they rolled those notes into their own Series C Preferred Stock 3, SRXH captured the explosive upside of CERo's immunotherapy pipeline, but they don't have to pay for the labs, scientists, or overhead. They just hold the high-tier equity. 4, undervalued at $1.71

$CERO Management should just brooker a buyout and move on